Pliant Therapeutics reports Q3 net loss of $41.5M; positive bexotegrast PSC interim data

PLIANT THERAPEUTICS, INC.

2023-Q3 EPS reported -$2.06 revenue$1,580,000

Net loss of $41.5M vs $30.6M in prior-year quarter; R&D expense $32.3M, G&A $15.3M.
Cash, cash equivalents and short-term investments of $523.6M, funding operations into H2 2026.
Positive 12-week data from Phase 2a INTEGRIS-PSC trial; 160 mg dose showed statistically significant reduction in ELF and PRO-C3 vs placebo.
DSMB recommended INTEGRIS-PSC continue without modification; 320 mg data expected Q1 2024.
Appointed Minnie Kuo as Chief Development Officer and Mishima Gerhart as Chief Regulatory Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLIANT THERAPEUTICS, INC. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLIANT THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001746473-23-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.